Clinical Scorecard: Industry Insights: Mark L. Baum, Founder and Chief Executive Officer, Harrow
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease |
| Key Mechanisms | Access facilitation to prescribed medications, reduction of administrative burdens. |
| Target Population | Patients requiring treatment for dry eye disease, particularly Medicare Part D patients. |
| Care Setting | Outpatient settings, including eyecare providers' offices. |
Key Highlights
- Vevye Access for All program expands access to Vevye for Klarity-C users.
- Patients can switch to Vevye for the same cost as Klarity-C.
- Program reduces out-of-pocket costs and administrative burdens for patients.
- Efficient prescription change process through PhilRx portal.
- 50% reduction in market price for Vevye at $59 per bottle.
Guideline-Based Recommendations
Diagnosis
- Assess patient need for dry eye disease treatment.
Management
- Facilitate access to Vevye through the Vevye Access for All program.
Monitoring & Follow-up
- Monitor patient access and adherence to prescribed medications.
Risks
- Prior authorizations and step therapy may hinder access.
Patient & Prescribing Data
Patients with dry eye disease, especially those on Medicare Part D.
Switching to Vevye can reduce overall treatment costs and improve access.
Clinical Best Practices
- Engage with patients and healthcare providers to understand access issues.
- Utilize the PhilRx portal for efficient prescription management.
- Stay informed about program expansions and partner pharmacies.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.